Innovative Therapeutics AIVITA Biomedical specializes in developing revolutionary cell-based treatments and personalized vaccines for cancer and infectious diseases like COVID-19, creating opportunities to collaborate on next-generation immunotherapies and vaccine solutions.

Growth & Funding With recent funding rounds and a revenue range of 10 to 25 million dollars, the company is positioned for expansion, presenting potential sales opportunities in clinical development services, partnerships, and specialized biotech supplies.

Leadership & Expertise Led by distinguished industry leaders including CEO Hans Keirstead and board member Michel Vounatsos, AIVITA's strong scientific and executive team indicates a focus on cutting-edge regenerative medicine, offering prospects for high-level collaborations and strategic partnerships.

Sustainability & Future Focus AIVITA's commitment to developing curative and regenerative medicines, along with next-generation skincare and vaccine platforms, positions it as a forward-thinking partner in the biotech space, opening doors for innovative product integrations and technology licensing deals.

Research & Development Active in pioneering personalized vaccines and neoantigen therapies, AIVITA offers opportunities for suppliers and service providers in stem cell research, vaccine manufacturing, and biotechnological innovation to support their clinical and commercial programs.